enVVeno Medical announces 57 patients enrolled to date in SAVVE study

enVVeno Medical provided an update on enrollment for its ongoing SAVVE U.S. pivotal study for the VenoValve and announced two upcoming investor events. The SAVVE pivotal study is a prospective, non-blinded, single arm, multi-center study of 75 CVI patients. To date, the Company has enrolled 57 patients in the study and expects enrollment to be completed before the end of 2023. “We are very encouraged by the enrollment momentum we have created over the past few months, including the number of new patients currently being considered for SAVVE, and are confident that we will reach full enrollment by the end of the year,” commented Robert Berman, CEO. “The new patient enrollment initiatives that we implemented over the course of the study have resulted in significant progress in what is still a somewhat unpredictable and challenging hospital environment.”